

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

General Management Issues

TITLE: *Bio-orthogonal catalysis for cancer therapy*

ACRONYM: *THERACAT*

DURATION: *01/03/2018 – 28/02/2022 (4 years project)*

PROJECT ID: *765497*

FUNDED UNDER: *H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers*

TOPIC: *MSCA-ITN-2017 - Innovative Training Networks*

FUNDING SCHEME: *MSCA-ITN-ETN - European Training Networks*

USEFUL WEBSITES:

- *CORDIS Web:* <https://cordis.europa.eu/project/rcn/215989/factsheet/en>
- *THERCAT Web:* www.theracat.eu/
- *THERACAT Intranet:* <https://theracat.eu/wp-login.php>

CONFIDENTIAL FILES

RELEVANT DOCUMENTS (Available on the intranet):

- *GRANT AGREEMENT (GA, Declaration of Honour, Data sheet)*
- *CONSORTIUM AGREEMENT*

FUNDING & TENDERS PORTAL: NEW!

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>

The screenshot displays the 'My Project(s)' portal interface. On the left is a dark blue navigation sidebar with options: 'Manage my area', 'My Organisation(s)', 'GRANTS', 'My Proposal(s)', 'My Project(s)', and 'My Formal Notification(s)[1]'. The top header is dark blue with navigation links: 'SEARCH FUNDING & TENDERS', 'HOW TO PARTICIPATE', 'PROJECTS & RESULTS', 'WORK AS AN EXPERT', and 'SUPPORT'. A 'select programme' dropdown and a notification bell with '491' are also present.

The main content area features a 'My Project(s)' heading with a document icon. Below this are three buttons: 'Online manual "Grant management"', 'IT HOW TO "Grant management"', and 'More info'. A search bar contains 'spm2.0' and a 'Download excel list of those projects' button is visible.

The main data area is a table with the following columns: 'ACRONYM', 'CALL', 'PROGRAM', 'PROJECT', 'PHASE', and 'ACTIONS'. The table contains one row with the following data:

| ACRONYM | CALL | PROGRAM | PROJECT | PHASE | ACTIONS |
|------------|---------------------|---------|------------|--------|-----------|
| [Redacted] | H2020-MSCA-ITN-2016 | H2020 | [Redacted] | Active | 1 Actions |

 The 'ACTIONS' column for the first row has a dropdown menu open, showing options: 'Project Consortium', 'Manage Project' (indicated by a red arrow), and 'View Proposal'. A pagination bar at the bottom shows '1' of 10 items.

PERIODIC REPORTING AND CONTINUOUS REPORTING:

MY PROJECT

HORIZON 2020

Call: H2020-MSCA-ITN-2016
 Type of Action: MSCA-ITN-ETN
 Acronym: ██████████
 Current Phase: Grant Management
 Number: ██████████
 Duration: 48 months
 GA based on the: H2020 MGA MSCA-ITN Multi - 2.0
 Start Date: ██████████
 Estimated Project Cost: ██████████
 Requested EU Contribution: ██████████
 Contact: ██████████

Latest Legal Data
 Active Processes
 Document Library
 Communication Centre
 Archived Processes

Launch new interaction with the EU +

Periodic Reporting ↙

▶▶○ Draft ————— ○ Submitted ————— ○◀◀ Paid

- +
📄 Technical Part of Periodic Report review
 Unlock to draft
Accept & Include
- +
📄 Financial Part IBEC [PIC 999528450] drafting
 Lock for review
- +
📄 Periodic Report composition
 ✖ Submit to EU

▶ Process documents
▶ Process communications
▶ Process history

Continuous Reporting ↙

▶▶○ Started ————— ○◀◀ Completed

01 Jan 2017

- +
📄 Continuous reporting data

▶ Process documents
▶ Process communications
▶ Process history

PERIODIC REPORTING AND CONTINUOUS REPORTING:

MY PROJECT

HORIZON 2020

Call: H2020-MSCA-ITN-2016
 Type of Action: MSCA-ITN-ETN
 Acronym: ██████████
 Current Phase: Grant Management
 Number: ██████████
 Duration: 48 months
 GA based on the: H2020 MGA MSCA-ITN Multi - 2.0
 Start Date: ██████████
 Estimated Project Cost: ██████████
 Requested EU Contribution: ██████████
 Contact: ██████████

Latest Legal Data
 Active Processes
 Document Library
 Communication Centre
 Archived Processes

Launch new interaction with the EU +

Periodic Reporting ↙

▶▶○ Draft ————— ○ Submitted ————— ○◀◀ Paid

- +
G Technical Part of Periodic Report review
 Unlock to draft
Accept & Include
- +
AVC Financial Part IBEC [PIC 999528450] drafting
 Lock for review
- +
AVC Periodic Report composition
 ✗ Submit to EU

▶ Process documents
▶ Process communications
▶ Process history

Continuous Reporting

▶▶○ 01 Jan 2017 Started ————— ○◀◀ Completed

- +
AVC Continuous reporting data

▶ Process documents
▶ Process communications
▶ Process history

PERIODIC REPORTING:

- **Progress report (Month 13):** technical report – no financial. **DONE & APPROVED**
- **1st Periodic report (Month 24): TO BE DONE (MARCH 2020) – we will send e-mail & template**
 - Periodic technical report (Part A by the IT system, Part B “work done” as pdf)
 - Periodic financial report (explanation of the use of resources):
 - Individual Financial Statements (IFS)
 - Periodic summary financial statement
- **2nd Periodic report and final report (Month 48):**
 - Periodic technical & financial report
 - Final technical & financial report

All the IFS and the technical reports have to be submitted electronically in one package

Two-step submission process for Financial report:

- **Beneficiary → Coordinator → REA (No paper signed document, only electronic)**

Certificates on the financial statements (CFS) are not required for ITN projects for reporting purposes but financial distribution report might be requested in some specific cases (audit, recovery, etc.), please check GA.


PERIODIC REPORTING AND CONTINUOUS REPORTING:

MY PROJECT

HORIZON 2020

Call: H2020-MSCA-ITN-2016
 Type of Action: MSCA-ITN-ETN
 Acronym: ██████████
 Current Phase: Grant Management
 Number: ██████████
 Duration: 48 months
 GA based on the: H2020 MGA MSCA-ITN Multi - 2.0
 Start Date: ██████████
 Estimated Project Cost: ██████████
 Requested EU Contribution: ██████████
 Contact: ██████████

Latest Legal Data
 Active Processes
 Document Library
 Communication Centre
 Archived Processes

Launch new interaction with the EU 

Periodic Reporting

Draft Submitted Paid


Technical Part of Periodic Report review Unlock to draft Accept & Include

Financial Part IBEC [PIC 999528450] drafting Lock for review

Periodic Report composition Submit to EU

Process documents

Process communications

Process history 

Continuous Reporting

01 Jan 2017

Started Completed

Continuous reporting data

Process documents

Process communications

Process history

CONTINUOUS REPORTING to the FUNDING & TENDERS PORTAL:

During whole project life cycle, whenever needed (Part A):

- Deliverables
- Dissemination activity/Communication*
- Publications*
- Patents (IPR)*
- Publishable Summary (under development).
- Milestones (under development).
- Critical risks (under development).

We as coordinators update it with inputs from partners

Beneficiary must make it visible that their action received H2020 funding

Questionnaires:

- **Gender, SME impact.**

| Project Continuous Report | | | | | | | | | | |
|---------------------------|-----------------------------------------|------------|--------------|---------------|---------------|------------|--------|-------------|---------------------|----------------|
| Summary for publication | Deliverables Ethics, DMP, Other Reports | Milestones | Publications | Disseminat... | Patents (IPR) | SME Impact | Gender | Researchers | Training Activities | ABS Regulation |
| | | | | | | | | | | |

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Training

TRAINING PROGRAMME:

1. **Local Scientific Training activities**, provided by host institutions:

- **By whom:** ESR's Supervisor/s & PhD program, and by post-doctoral staff belonging to the host research group.
- **What:** All scientific, methodological and technical aspects relevant for the individual research project of the ESR and in which the host group is expert. Participation of ESRs in local training activities should be also promoted (e.g. seminars, complementary skills sessions, etc.).

2. **THERACAT Conference:** Barcelona, August-September 2021

- Lectures by the different PIs, ESRs and invited external experts.
- Open also to non-member students (c.a. 50 students including THERACAT ESRs).
- Satellite of the NanoBio&Med conference in Barcelona (**to be confirmed**).

TRAINING PROGRAMME:

3. **Secondments** to other partner's laboratories:

- Takes place in an institution different from the host institution.
- Between members of the network with complementary expertise and nature.
- Fellows will be exposed to different disciplines and sectors (academic/industrial).
- **Secondments are MANDATORY:** Exceptions could be considered due to *force majeure* issues but PO must be informed in advance (contact IBEC as coordinator).
- **Secondment details must be uploaded at the “Funding & Tenders” Portal by each beneficiary.**
- Define the work to be performed and specific dates with the host institution in advance (**include IBEC in CC**).

4. **Network-wide** scientific/complementary skills **courses (Training Events, TE):**

- Multidisciplinary content adapted to the different backgrounds of ESRs.
- The course organizer will be responsible to define the detailed content of the course, the schedule and the lecturers participating in it.
- Five **Training Events** (duration 4-5 days) hosted by a beneficiary.
- TE may be open to PhD students from outside the network.

TRAINING PROGRAMME:

3. **Secondments** to other partner's laboratories:

- Takes place in an institution different from the host institution.
- Between members of the network with complementary expertise and nature.
- Fellows will be exposed to different disciplines and sectors (academic/industrial).
- **Secondments are MANDATORY:** Exceptions could be considered due to *force majeure* issues but PO must be informed in advance (contact IBEC as coordinator).
- **Secondment details must be uploaded at the “Funding & Tenders” Portal by each beneficiary.**
- Define the work to be performed and specific dates with the host institution in advance (**include IBEC in CC**).

4. **Network-wide scientific/complementary skills courses (Training Events, TE):**

- Multidisciplinary content adapted to the different backgrounds of ESRs.
- The course organizer will be responsible to define the detailed content of the course, the schedule and the lecturers participating in it.
- Five **Training Events** (duration 4-5 days) hosted by a beneficiary.
- TE may be open to PhD students from outside the network.

| Date | 01/20 | | | | | 06/20 | | | | | | 12/20 | 01/21 | | | | | 06/21 | | | | | | | 12/21 | 01/22 | |
|------------------------------|-------|----|----|----|----|-------|----|----|----|----|----|-------|-------|----|----|----|----|-------|----|----|----|----|----|----|-------|-------|--|
| Months | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | |
| ESR1-GRO (M. Vargiu) | | | | | S | S | S | | | | | | | | | | I | I | I | | | | | | | | |
| ESR2-TAU (S. Wagle) | | S | S | S | | | | | | | | | | I | I | I | I | | | | | | | | | | |
| ESR3-TEVA (K. Vippala) | | | | | | | | | I | I | I | I | | | | | | | | | I | I | I | | | | |
| ESR4-TUE (A. Sathyan) | | | | | S | S | S | | | | | | I | I | I | | | | | | | | | | | | |
| ESR5-EDI (S. Croke) | | | | | I | I | I | I | | | | | | | S | S | S | | | | | | | | | | |
| ESR6-TUE (M. Arxontakis) | | | | | | | | | S | S | S | | | | | | | | | | | | I | I | I | | |
| ESR7-IBEC (A. Olea) | | | | | | I | I | I | | | | | | | S | S | S | S | | | | | | | | | |
| ESR8-TUE (L. Deng) | | | S | S | S | S | | | | | | | | | | | | I | I | I | | | | | | | |
| ESR9-BGX (A. Galvez) | | | | | | | | I | I | I | | | | | | | I | I | I | I | | | | | | | |
| ESR10-BAS (B. Lozhkin) | | | | | | S | S | S | | | | | | | I | I | I | | | | | | | | | | |
| ESR11-EDI (M. van de L'Isle) | | I | I | I | | | | | | | | | | | | S | S | S | | | | | | | | | |
| ESR12-TAG (M. Vlastara) | | I | I | I | | | | | I | I | I | | | | | | | | | | | | | | | | |
| ESR13-TAU (D. Rodriguez) | | | S | S | S | S | | | | | | | | | I | I | I | | | | | | | | | | |

Next 12 months secondments: **please revise them carefully**

- **ESR1 (GRO):** EDI – Prodrug uncaging in vitro (M27, 3 months)
- **ESR2 (TAU):** GRO – Metal catalyst synthesis (M24, 3 months); TAG – in vivo micelle imaging (M36, 4 months)
- **ESR3 (TEVA):** IBEC – NP imaging (M31, 4 months)
- **ESR4 (TUE):** BAS – synthesis of Ru catalysts (M27, 3 months); TEVA – industrial formulation of SCPN (M35, 3 months).
- **ESR5 (EDI):** TAG – Pro-imaging PET agents (M27, 4 months)

| Date | 01/20 | | | | | 06/20 | | | | | | 12/20 | 01/21 | | | | | 06/21 | | | | | | | 12/21 | 01/22 |
|------------------------------|-------|----|----|----|----|-------|----|----|----|----|----|-------|-------|----|----|----|----|-------|----|----|----|----|----|----|-------|-------|
| Months | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 |
| ESR1-GRO (M. Vargiu) | | | | | S | S | S | | | | | | | | | | I | I | I | | | | | | | |
| ESR2-TAU (S. Wagle) | | S | S | S | | | | | | | | | | I | I | I | I | | | | | | | | | |
| ESR3-TEVA (K. Vippala) | | | | | | | | | I | I | I | I | | | | | | | | | I | I | I | | | |
| ESR4-TUE (A. Sathyan) | | | | | S | S | S | | | | | | I | I | I | | | | | | | | | | | |
| ESR5-EDI (S. Croke) | | | | | I | I | I | I | | | | | | | S | S | S | | | | | | | | | |
| ESR6-TUE (M. Arxontakis) | | | | | | | | | S | S | S | | | | | | | | | | | | I | I | I | |
| ESR7-IBEC (A. Olea) | | | | | | I | I | I | | | | | | | S | S | S | S | | | | | | | | |
| ESR8-TUE (L. Deng) | | | S | S | S | S | | | | | | | | | | | | | I | I | I | | | | | |
| ESR9-BGX (A. Galvez) | | | | | | | | I | I | I | | | | | | | I | I | I | I | | | | | | |
| ESR10-BAS (B. Lozhkin) | | | | | | S | S | S | | | | | | | I | I | I | | | | | | | | | |
| ESR11-EDI (M. van de L'Isle) | | I | I | I | | | | | | | | | | | | S | S | S | | | | | | | | |
| ESR12-TAG (M. Vlastara) | | I | I | I | | | | | I | I | I | | | | | | | | | | | | | | | |
| ESR13-TAU (D. Rodriguez) | | | S | S | S | S | | | | | | | | | I | I | I | | | | | | | | | |

Next 12 months secondments: **please revise them carefully**

- **ESR6 (TUE):** GRO – synthesis of SCPN for imaging (M31, 3 months)
- **ESR7 (IBEC):** BGX – imaging of gel models (M28, 3 months)
- **ESR8 (TUE):** IBEC – STORM imaging of SCPN delivery (M25, 4 months)
- **ESR9 (BGX):** TUE – synthesis of gel-based catalysts (M30, 3 months)
- **ESR10 (BAS):** EDI – synthesis of caged prodrugs (M28, 3 months)
- **ESR11 (EDI):** BGX – gel-based implants (M24, 3 months)

| Date | 01/20 | | | | | 06/20 | | | | | | | 12/20 | 01/21 | | | | | | 06/21 | | | | | | | 12/21 | 01/22 |
|------------------------------|-------|----|----|----|----|-------|----|----|----|----|----|----|-------|-------|----|----|----|----|----|-------|----|----|----|----|----|----|-------|-------|
| Months | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | | |
| ESR1-GRO (M. Vargiu) | | | | | S | S | S | | | | | | | | | | I | I | I | | | | | | | | | |
| ESR2-TAU (S. Wagle) | | S | S | S | | | | | | | | | | I | I | I | I | | | | | | | | | | | |
| ESR3-TEVA (K. Vippala) | | | | | | | | | I | I | I | I | | | | | | | | | I | I | I | | | | | |
| ESR4-TUE (A. Sathyan) | | | | | S | S | S | | | | | | I | I | I | | | | | | | | | | | | | |
| ESR5-EDI (S. Croke) | | | | | I | I | I | I | | | | | | | S | S | S | | | | | | | | | | | |
| ESR6-TUE (M. Arxontakis) | | | | | | | | | S | S | S | | | | | | | | | | | | I | I | I | | | |
| ESR7-IBEC (A. Olea) | | | | | | I | I | I | | | | | | | S | S | S | S | | | | | | | | | | |
| ESR8-TUE (L. Deng) | | | S | S | S | S | | | | | | | | | | | | | I | I | I | | | | | | | |
| ESR9-BGX (A. Galvez) | | | | | | | | I | I | I | | | | | | | I | I | I | I | | | | | | | | |
| ESR10-BAS (B. Lozhkin) | | | | | | S | S | S | | | | | | | I | I | I | | | | | | | | | | | |
| ESR11-EDI (M. van de L'Isle) | | I | I | I | | | | | | | | | | | | S | S | S | | | | | | | | | | |
| ESR12-TAG (M. Vlastara) | | I | I | I | | | | | I | I | I | | | | | | | | | | | | | | | | | |
| ESR13-TAU (D. Rodriguez) | | | S | S | S | S | | | | | | | | | I | I | I | | | | | | | | | | | |

Next 12 months secondments: **please revise them carefully**

- **ESR12 (TAG):** EDI – pro-PET agents synthesis (M24, 3 months); BAS – activable PET probe (M31, 3 months).
- **ESR13 (TAU):** IBEC – imaging of ex-vivo samples (M25, 4 months)

TRAINING PROGRAMME:

3. **Secondments** to other partner's laboratories:

- Takes place in an institution different from the host institution.
- Between members of the network with complementary expertise and nature.
- Fellows will be exposed to different disciplines and sectors (academic/industrial).
- **Secondments are MANDATORY:** Exceptions could be considered due to *force majeure* issues but PO must be informed in advance (contact IBEC as coordinator).
- **Secondment details must be uploaded at the “Funding & Tenders” Portal by each beneficiary.**
- Define the work to be performed and specific dates with the host institution in advance (**include IBEC in CC**).

4. **Network-wide scientific/complementary skills courses (Training Events, TE):**

- Multidisciplinary content adapted to the different backgrounds of ESRs.
- The course organizer will be responsible to define the detailed content of the course, the schedule and the lecturers participating in it.
- Five **Training Events** (duration 4-5 days) hosted by a beneficiary.
- TE may be open to PhD students from outside the network.

TRAINING EVENT 3 (TE3):

- Hosted by EDI.
- Month 24: 4th – 7th February 2020
- 4 days.
- Coinciding with Network Meeting 2 (current).

| 3 – Drug delivery & microscopy | M24, 5 days | 2 ECTS | EDI |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-------------|--------|
| Content: This training event will focus on the design of polymeric platforms for delivering the catalysts and on in-vitro imaging, which is utilized for preliminary evaluation of the performance of the proposed therapeutic approach. | | | |
| Designing delivery systems: concepts, examples and concerns | TAU (R. Amir) | SCI | 1 day |
| Introduction to in-vitro imaging and cell assays | EDI (A.Unciti-Broceta) | SCI | 1 day |
| The power of microscopy techniques in biomedical research: principles and challenges | IBEC (L.Albertazzi) | SCI | 1½ day |
| Lab tours in a microscopy facility including hands-on experience | EDI (EDI lab members) | LAB | ½ day |
| Gender balance in academia, current situation and future perspectives | UAB (J.Gallego) | COMP | ½ day |
| ESR Meeting 2 | ESR representatives | - | ½ day |

TRAINING EVENT 4 (TE4):

- Hosted by TAU.
- Month 30 (August 2020).
- 5 days.

DEFINE DATES!!

| 4 – Going in vivo, chemistry and cancer biology | M30, 5 days | 2 ECTS | TAU |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|----------|-------|
| Content: This training event will give broader introduction to cancer and will focus on the different aspects of developing in vivo models and pharmacological studies for the proposed therapeutics. | | | |
| Fighting Cancer – biomedical, social and economic aspects | CRUK (F.Ratcliffe) | SCI COMP | 1 day |
| Animal experiments – ethical and practical aspects | TAU (R.Satchi-Fainaro) | SCI LAB | 1 day |
| Designing in vivo models and choosing the right controls | TAU (R.Satchi-Fainaro) | SCI | 1 day |
| In Vivo imaging | TAG (M.Robillard) | SCI | 1 day |
| How to communicate to and engage the public | CRUK (F.Ratcliffe) | COMP | ½ day |
| ESR Meeting 3 | ESR representatives | - | ½ day |

TRAINING EVENT 5 (TE5):

- Hosted by IBEC.
- Month 36 (February 2021).
- 7 days.
- Coinciding with Network Meeting 3.

| 5 – Getting ready for the next career step | M36, 7 days | 3 ECTS | IBEC |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-------------|--------|
| Content: The last training event will be dedicated to preparing the ESRs towards completion of their studies and the development of their independent careers in industry, academia and EU agencies, including job hunting. | | | |
| Career opportunities in industry and interview simulations | Industrial PIs | COMP | 1½ day |
| Searching for post-doc and setting the path for academic careers | Academic PIs | COMP | 1 day |
| Innovation and Entrepreneurship including managing strategies, IPs, financing and marketing. | ESADE (J.Vinaixa) | COMP | 4 day |
| ESR Meeting 4 | ESR representatives | - | ½ day |

GENERAL ASPECTS:

- Each ESR will be assigned an **Assessment Commission (AC)** composed of 3 members belonging to partners other than the host partner and with different profiles (academic/non-academic).
- The ACs will meet with the ESR three times coinciding with Network Meetings 1, 2 and 3 and will have as main mission to offer a broader perspective to the training and research being carried by the ESR. It will also act as intermediate to solve conflicts or misconduct issues between the ESR and supervisor.
- ACs:
 - ESRs will send a short report describing the training received and research performed to both the AC members and to the Coordinator, including main obstacles and future plans (every 6 months). Template will be provided.
 - First assessment (1st Network Meeting): ACs will evaluate and discuss ERS's PCDP, their integration in the host institution and initial results of the research (if any).
 - Second assessment (2nd Network Meeting): the ESR will report on the evolution of its research project and of the results obtained.
 - Third assessment (3rd Network Meeting): the ESR will present the main conclusions on the work obtained so far and a draft version of the PhD thesis (preliminary).
 - Recommendations of the AC will be forwarded to the ESR and his/her supervisor (e.g. specific training events interesting for the ESR, best practices that could be implemented in the following period). Template will be provided.

ASSESSMENT COMMISSIONS COMPOSITION: General groups

| ESR / AC | <u>Assessment Commission 1</u> TAU-b (Satchi-Fainaro) GRO TEVA | <u>Assessment Commission 2</u> TUE EDI TAG | <u>Assessment Commission 3</u> BAS IBEC BGX TAU-a (Amir) |
|-------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------------------------|
| ESR1 (GRO) | | X | |
| ESR2 (TAU-a; Amir) | | X | |
| ESR3 (TEVA) | | | X |
| ESR4 (TUE) | X | | |
| ESR5 (EDI) | X | | |
| ESR6 (TUE; Albertazzi) | X | | |
| ESR7 (IBEC) | | X | |
| ESR8 (TUE) | | | X |
| ESR9 (BGX) | | X | |
| ESR10 (BAS) | X | | |
| ESR11 (EDI) | | | X |
| ESR12 (TAG) | | | X |
| ESR13 (TAU-b; Satchi-Fainaro) | | | X |

ASSESSMENT COMMISSIONS COMPOSITION:

| Fellow | Assessment Commission member |
|------------------------------------------------|---------------------------------------------|
| ESR1 – Michela Vargiu (GRO) | Asier Unciti |
| ESR2 – Shreyas Wagle (TAU; Amir) | Marc Robillard |
| ESR3 – Krishna Vippala (TEVA) | Lorenzo Albertazzi |
| ESR4 – Anjana Sathyan (TUE) | Galia Tiram (TAU) |
| ESR5 – Stephen Croke (EDI) | Bianca Avramovitch |
| ESR6 – Manos Archontakis (TUE; Albertazzi) | Bianca Avramovitch |
| ESR7 – Alis Olea (IBEC) | Asier Unciti |
| ESR8 – Linlin Deng (TUE) | Chris Allan |
| ESR9 – Africa Galvez (BGX) | Anja Palmans |
| ESR10 – Boris Lozhkin (BAS) | Gerard Roelfes Galia Tiram (TAU) |
| ESR11 – Melissa van de L’Isle (EDI) | Roey Amir |
| ESR12 – Maria Vlastara (TAG) | Thomas Ward |
| ESR13 – Daniel Rodríguez (TAU; Satchi-Fainaro) | Lorenzo Albertazzi |

Please each supervisor remember to give some feedback to the assigned fellow based on his/her presentation in the AC session this afternoon

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Next Meetings and Events

| Month | Date | Place | Duration | Meeting | Attendees |
|-------|------------------------------------|-------|----------|----------------------------------------|---------------------|
| M01 | May 31 st , 2018 | IBEC | 1 day | Kick-off Meeting | PIs |
| M12 | March 25 – 29 th , 2019 | TUE | 1 day | Meeting 1 | ESRs & PIs |
| | | | 4 days | Training Event 1 | ESRs & PIs involved |
| M16 | June 5 th , 2019 | EDI | 1 day | Mid-Term Check Meeting with PO from EC | ESRs & PIs |
| M18 | Sept. 23 – 27 th , 2019 | BAS | 5 days | Training Event 2 | ESRs & PIs involved |
| M24 | February 2020 | EDI | 1 ½ day | Meeting 2 | ESRs & PIs |
| | | | 5 days | Training Event 3 | ESRs & PIs involved |
| M30 | August 2020 | TAU | 5 days | Training Event 4 | ESRs & PIs involved |
| M36 | February 2021 | IBEC | 1 ½ day | Meeting 3 | ESRs & PIs |
| | | | 7 days | Training Event 5 | ESRs & PIs involved |
| M42 | August 2021 | IBEC | 1-2 days | THEACAT conference | ESRs & PIs |
| M48 | February 2022 | IBEC | 1 ½ day | Final Meeting | ESRs & PIs |

| Month | Date | Place | Duration | Meeting | Attendees |
|-------|------------------------------------|-------|----------|----------------------------------------|---------------------|
| M01 | May 31 st , 2018 | IBEC | 1 day | Kick-off Meeting | PIs |
| M12 | March 25 – 29 th , 2019 | TUE | 1 day | Meeting 1 | ESRs & PIs |
| | | | 4 days | Training Event 1 | ESRs & PIs involved |
| M16 | June 5 th , 2019 | EDI | 1 day | Mid-Term Check Meeting with PO from EC | ESRs & PIs |
| M18 | Sept. 23 – 27 th , 2019 | BAS | 5 days | Training Event 2 | ESRs & PIs involved |
| M24 | February 2020 | EDI | 1 ½ day | Meeting 2 | ESRs & PIs |
| | | | 5 days | Training Event 3 | ESRs & PIs involved |
| M30 | August 2020 | TAU | 5 days | Training Event 4 | ESRs & PIs involved |
| M36 | February 2021 | IBEC | 1 ½ day | Meeting 3 | ESRs & PIs |
| | | | 7 days | Training Event 5 | ESRs & PIs involved |
| M42 | August 2021 | IBEC | 1-2 days | THEACAT conference | ESRs & PIs |
| M48 | February 2022 | IBEC | 1 ½ day | Final Meeting | ESRs & PIs |

Network Meetings:

- The typical duration of a Network Meeting will be **one day and a half**.
- **Progress monitoring** of the Network (short presentations by ESR fellows).
- Evaluation of scientific progress by Supervisory Board.
- **Assessment Commissions:** evaluate individual scientific and training progress of ESRs.
- Meetings will be responsibility of the host institution.
- Network Meetings will coincide with Training Events.
- Meetings shall be convened by the Coordinator with at least 45 days prior notice.
- Minutes of Meetings will be prepared by the Project Manager (15 days for approval).

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Dissemination and Communication Actions

SCIENTIFIC PUBLICATIONS:

- Journals in the fields of chemical synthesis and catalysis, drug delivery and cancer research will be targeted as well as multidisciplinary journals.
- [Open Science](#) (Open Access journals, repositories (green way), gold way). **Each institution is responsible to publish in Open Access. Please contact us in case of any doubt.**

CONFERENCES:

Biennial International Symposium on Medicinal Chemistry (EFMC-ISMC), National Meetings organized by the ACS, international cancer meetings (e.g. AACR Annual Meetings) and drug discovery meetings (e.g. BPS, ELRIG and MlpTec meetings), NanoBioMed Conference (IBEC), international symposium on bio-orthogonal strategies (CRUK – RSC).

INSTITUTIONS WEBSITES & THERACAT WEBSITE:

Research findings will be highlighted in the consortium labs' websites (e.g. www.boomchemistry.com, <http://www.ibecbarcelona.eu>, <http://www.meijerlab.nl>), CRUK's website and THERACAT website (<https://theracat.eu/>).

SCIENTIFIC PUBLICATIONS:

- Journals in the fields of chemical synthesis and catalysis, drug delivery and cancer research will be targeted as well as multidisciplinary journals.
- [Open Science](#) (Open Access journals, repositories (green way), gold way). **Each institution is responsible to publish in Open Access. Please contact us in case of any doubt.**

CONFERENCES:

Biennial International Symposium on Medicinal Chemistry (EFMC-ISMC), National Meetings organized by the ACS, international cancer meetings (e.g. AACR Annual Meetings) and drug discovery meetings (e.g. BPS, ELRIG and MlpTec meetings), NanoBioMed Conference (IBEC), international symposium on bio-orthogonal strategies (CRUK – RSC).

INSTITUTIONS WEBSITES & THERACAT WEBSITE:

Research findings will be highlighted in the consortium labs' websites (e.g. www.boomchemistry.com, <http://www.ibecbarcelona.eu>, <http://www.meijerlab.nl>), CRUK's website and THERACAT website (<https://theracat.eu/>).

- Inform us of any dissemination activity performed (conference, news in websites, etc.).
- Partners TEVA (Bianca), IBEC (Lorenzo) and TAU (Ronit) please send us feedback on dissemination & communication actions as requested
- Remember that the only activities considered by the EC are those performed by the ESRs!

THERACAT WEBPAGE: done

SOCIAL MEDIA: The results of THERACAT will be communicated to the public through social media such as Facebook, Twitter and LinkedIn. **THERACAT account to be created**

BLOGS: Several THERACAT institutions such as IBEC and CRUK publish divulgation blogs. These platforms will be used to disseminate the results in a simple and comprehensible way to the general public.

VIDEOS: ESRs in collaboration with TUE will prepare videos explaining for a general audience the main goals of the project, its societal implications as well as promoting the value of mobility on a personal example. **Deliverable 8.4 (month 24, Feb 2020). Discuss: Fellows involved?**

GENERAL PRESS ARTICLES: about the research being conducted and its implications will be submitted to media such as CORDIS website and related webs (News, research*eu results magazine, Horizon Magazine). **D8.5 (M30, Aug 2020) & 8.9 (M48, Feb 2022). Discuss: Pls/fellows involved?**

SCIENCE FESTIVALS: Members of the consortium will participate to public events such as: the Edinburgh International Science Festival, the European Researchers' Night, and Night of art and Science in Groningen. **Sept 2020 European Researchers' Night (participants?)**

LOCAL MEDIA: The students will also promote their works in university newsletters, local press or radio/TV programmes to inform the general public of the discoveries and benefits related to the project proposed herein.

ACKNOWLEDGEMENT OF EU FUNDING:

Use EU emblem:

- High-resolution emblems are available here

<http://europa.eu/about-eu/basic-information/symbols/flag/>



Use text as indicated in GA:

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 765497 (THERACAT).

Or equivalent paragraph

MSCA-ITN-2017 - Innovative Training Networks



Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Deliverables and Milestones alignment

DELIVERABLES (Art. 19 of the GA):

- To be uploaded directly to the “Funding & Tenders” Portal by the Coordinator.
- All deliverables will be also uploaded on the THERACAT intranet.
- Scientific deliverables and other deliverables as defined in the GA Annex 1.
- In case of an update of a deliverable, the PO needs to be notified and re-opens the session.
- Procedure:
 - Template available on the THERACAT intranet.
 - Coordinator will inform deliverable’s leader 2 months before the deadline.

MILESTONES (Art. 20.3 of the GA):

- To be reported to the PO. Status of milestones will be updated on project intranet.
- Procedure:
 - Coordinator will advise milestone’s leader 2 months before the deadline.
 - **If milestone not achieved, review contingency plans & alternatives.**

SCIENTIFIC & MANAGEMENT DELIVERABLES: already submitted (13 MGT + 8 RTD)

| # | TITLE | LEADER | MONTH | STATUS | NATURE | RTD or MGT |
|------|---------------------------------------------------------------------------------------------------------------------------------|--------|-------|------------|--------------|------------|
| D2.1 | Network Meetings minutes (kick-off) | IBEC | 1 | Approved | Confidential | MGT |
| D2.2 | Consortium Agreement | IBEC | 2 | Under rev. | Confidential | MGT |
| D2.3 | Supervisory Board of the network | IBEC | 2 | Approved | Confidential | MGT |
| D8.1 | Website completion | EDI | 6 | Under rev. | Public | MGT |
| D7.1 | Personal Career Development Plans | IBEC | 10 | Under rev. | Confidential | MGT |
| D1.1 | A - Requirement No. 1 | IBEC | 12 | Under rev. | Confidential | RTD |
| D1.2 | NEC - Requirement No. 2 | IBEC | 12 | Under rev. | Confidential | RTD |
| D1.3 | HCT - Requirement No. 3 | IBEC | 12 | Under rev. | Confidential | RTD |
| D2.4 | Network Meetings minutes (Meeting 1) | IBEC | 12 | Under rev. | Confidential | MGT |
| D2.5 | Recruitment completion | TU/e | 12 | Under rev. | Confidential | MGT |
| D7.2 | Training events minutes | TAU | 12 | Under rev. | Public | MGT |
| D7.3 | ESRs periodic short reports and AC recommendations (M12) | IBEC | 12 | Under rev. | Confidential | MGT |
| D8.2 | Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12) | EDI | 12 | Under rev. | Confidential | MGT |
| D2.6 | Progress Report | IBEC | 13 | Under rev. | Confidential | MGT |
| D3.1 | Novel metal complexes for bio-orthogonal catalysis | GRO | 16 | Under rev. | Confidential | RTD |
| D4.1 | Library of anticancer prodrugs | EDI | 16 | Under rev. | Confidential | RTD |
| D5.1 | Library of targeted catalysts carriers | TU/e | 18 | Under rev. | Confidential | RTD |
| D6.1 | Set of mCherry-labeled orthotopic models of cancer in mice | TAU | 18 | Under rev. | Confidential | RTD |
| D7.4 | Training events minutes (Training event 2) | TAU | 18 | Under rev. | Public | MGT |
| D7.5 | ESRs periodic short reports and AC recommendations (M18) | IBEC | 18 | Under rev. | Confidential | MGT |
| D6.2 | Results of the biocompatibility tests for the catalysts | TAU | 22 | Under rev. | Confidential | RTD |

SCIENTIFIC & MANAGEMENT DELIVERABLES: imminent submission

| # | TITLE | LEADER | MONTH | STATUS | NATURE | RTD OR MGT |
|------|---------------------------------------------------------------------------------------------------------------------------------|--------|-------|---------|--------------|------------|
| D2.7 | Network Meetings minutes (Meeting 2) | IBEC | 24 | PENDING | Confidential | MGT |
| D7.6 | Training events minutes (Training event 3) | TAU | 24 | PENDING | Public | MGT |
| D7.7 | ESRs periodic short reports and AC recommendations (M24) | IBEC | 24 | PENDING | Confidential | MGT |
| D7.8 | Updated Personal Career Development Plans (M24) | IBEC | 24 | PENDING | Confidential | MGT |
| D8.3 | Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24) | EDI | 24 | PENDING | Confidential | MGT |
| D8.4 | THERACAT video | IBEC | 24 | PENDING | Public | MGT |

SCIENTIFIC & MANAGEMENT DELIVERABLES: imminent submission

| # | TITLE | LEADER | MONTH | STATUS | NATURE | RTD OR MGT |
|------|---------------------------------------------------------------------------------------------------------------------------------|--------|-------|---------|--------------|------------|
| D2.7 | Network Meetings minutes (Meeting 2) | IBEC | 24 | PENDING | Confidential | MGT |
| D7.6 | Training events minutes (Training event 3) | TAU | 24 | PENDING | Public | MGT |
| D7.7 | ESRs periodic short reports and AC recommendations (M24) | IBEC | 24 | PENDING | Confidential | MGT |
| D7.8 | Updated Personal Career Development Plans (M24) | IBEC | 24 | PENDING | Confidential | MGT |
| D8.3 | Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M24) | EDI | 24 | PENDING | Confidential | MGT |
| D8.4 | THERACAT video | IBEC | 24 | PENDING | Public | MGT |

- All of them prepared by IBEC
- **Fellows: update the PCDP according to the progress of the project & feedback received in Assessment Commissions (e-mail will be sent)**

SCIENTIFIC & MANAGEMENT DELIVERABLES: next 12 months

Please revise them and let us know any potential delay

| # | TITLE | LEADER | MONTH | NATURE | RTD OR MGT |
|-------|---------------------------------------------------------------------------------------------------------------------------------|--------|-------|--------------|------------|
| D4.2 | Set of 2-3 fluorescent probes | IBEC | 28 | Confidential | RTD |
| D3.2 | Novel nanostructures loaded with Ru or Pd catalysts | TEVA | 28 | Confidential | RTD |
| D5.2 | Description of the structure-activity relations of the material-cell interactions | IBEC | 30 | Confidential | RTD |
| D7.10 | ESRs periodic short reports and AC recommendations (M30) | IBEC | 30 | Confidential | MGT |
| D8.5 | General press articles submitted to EU magazines (M30) | IBEC | 30 | Public | MGT |
| D7.9 | Training events minutes (Training event 4) | TAU | 30 | Public | MGT |
| D5.3 | Selection of the best catalyst in vitro | BGX | 36 | Confidential | RTD |
| D8.6 | Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M36) | EDI | 36 | Confidential | MGT |
| D2.8 | Network Meetings minutes (Meeting 3) | IBEC | 36 | Confidential | MGT |
| D7.12 | Updated Personal Career Development Plans (M36) | IBEC | 36 | Confidential | MGT |
| D7.13 | ESRs periodic short reports and AC recommendations (M36) | IBEC | 36 | Confidential | MGT |
| D6.3 | Results of in vivo imaging of catalysts localization and efficacy | TAG | 36 | Confidential | RTD |
| D7.11 | Training events minutes (Training event 5) | TAU | 36 | Public | MGT |

MSCA-ITN-2017 - Innovative Training Networks




Marie Skłodowska-Curie
Actions



Bio-orthogonal catalysis for cancer therapy

Reporting


MONITORING PROJECT IMPLEMENTATION:



FUNDING & TENDERS PORTAL (PP):

- Project Reports
- Researchers declarations for all researchers.
- Other documents (Amendment, any other formal notifications...).
- Two-step submission process for Financial report:
 - Beneficiary → Coordinator → REA (No paper signed document, only electronic)

MONITORING PROJECT IMPLEMENTATION:



FUNDING & TENDERS PORTAL:

- Project Reports
- Researchers declarations for all researchers.
- Other documents (Amendment, any other formal notifications...).
- Two-step submission process for Financial report:
 - Beneficiary → Coordinator → REA (No paper signed document, only electronic)

RESEARCHER DECLARATION (RD):

- Mandatory by the EC (Art. 19 of the GA)
- Any new employment contract for the existing researcher requires a new RD.
- In case of any change (long sick leaves, maternity/parental leave, etc.) in the employment contract, the RD should be updated.
- **Please check that dates are correct: DATES INCLUDED IN RD ARE THE ONES CONSIDERED BY EC FOR PAYMENTS**

| First Name | Last Name | Status | Recruitment Organisation | Start Date | End Date | Working Time Cc | Duration |
|-------------|---------------|-----------|-------------------------------------------------|------------|------------|-----------------|----------|
| Rodica Alis | Olea | SUBMITTED | Fundacio Institut De Bioenginyeria De Catalunya | 16-10-2018 | 15-10-2021 | Full Time | 36 |
| Shreyas | Wagle | SUBMITTED | Tel Aviv University | 21-11-2018 | 20-11-2021 | Full Time | 36 |
| Boris | Lozhkin | SUBMITTED | Universitat Basel | 01-12-2018 | 30-11-2021 | Full Time | 36 |
| Michela | Vargiu | SUBMITTED | Rijksuniversiteit Groningen | 01-01-2019 | 31-12-2021 | Full Time | 36 |
| Africa | Galvez Flores | SUBMITTED | Biogelx Limited | 14-01-2019 | 12-01-2022 | Full Time | 36 |
| Maria | Vlastara | SUBMITTED | Tagworks Pharmaceuticals Bv | 15-01-2019 | 14-01-2022 | Full Time | 36 |
| Melissa | van de L'Isle | SUBMITTED | The University Of Edinburgh | 01-02-2019 | 31-01-2022 | Full Time | 36 |
| Stephen | Croke | SUBMITTED | The University Of Edinburgh | 12-11-2018 | 11-11-2021 | Full Time | 36 |
| Linlin | Deng | SUBMITTED | Technische Universiteit Eindhoven | 11-03-2019 | 28-02-2022 | Full Time | 35.6 |
| Anjana | Sathyan | SUBMITTED | Technische Universiteit Eindhoven | 01-01-2019 | 31-12-2021 | Full Time | 36 |
| Daniel | Rodriguez | SUBMITTED | Tel Aviv University | 09-12-2018 | 08-12-2021 | Full Time | 36 |
| Emmanouil | Archontakis | SUBMITTED | Technische Universiteit Eindhoven | 01-03-2019 | 28-02-2022 | Full Time | 36 |
| Krishna | Vippala | SUBMITTED | Teva Pharmaceutical Industries Limited | 04-09-2019 | 28-02-2022 | Full Time | 29.83 |

RESEARCHER DECLARATION: At the recruitment and if any change occurs

The screenshot displays a web application window titled "New Researcher Declaration" with a dark header bar containing "Gender" and "Researchers" tabs. Below the header, there are three tabs: "Researcher Information", "Recruitment Information", and "Recruitment Period". The "Recruitment Period" tab is active, showing a list of recruitment periods. Each period has fields for "Start Date", "End Date", and "Working Time Commitment".

Recruitment Period 1 is filled out with the following data:

- Start Date: 04-10-2016
- End Date: 12-10-2016
- Working Time Commitment: Full Time

A dropdown menu is open for the "Working Time Commitment" field, showing the following options:

- Full Time
- Suspension
- Part Time
- Maternity Leave
- Paternity Leave

To the right of the dropdown menu, a text box lists the following options:

- Full Time (100%)
- Suspension (0%)
- Part time (1 - 99%)
- Maternity Leave (0%)
- Paternity Leave (0%)

Recruitment Period 2 and Recruitment Period 3 are currently empty. At the bottom of the form, there are "OK" and "Cancel" buttons.

PARENTAL AND MATERNITY LEAVE:

- Yes, in accordance with national legislation.
- The researcher's activity in the action is **suspended** during the maternity/parental leave.

SICK LEAVE:

- Yes, in accordance with national legislation.
- Are the costs of the leave eligible under the action?
 - For short-term leave (≤ 1 month).
 - Unit is eligible, 100%.
 - For long-term leave (> 1 month):
 - For the period that employer has to pay 100% of fellow's salary per national law → unit is eligible, 100%.
 - For the period that employer has to pay a percentage (e.g. 50%) of fellow's salary per national law → unit is eligible, 50%.
 - For the period that employer does not have to pay the fellow's salary per national law → researcher's activity in the action is **suspended**.

We will evaluate it case by case if it happens. Please contact us

RECORDS we need to prove the number of units declared:

- Evidence of open, transparent recruitment.
- Evidence of the eligibility of the fellow in terms of researcher experience, mobility and family status (e.g. CVs, copies of diplomas, ...)
- Employment contract/agreement with the fellow.
- Proof of payment of the researcher's allowances and of the deductions for social security etc.
- Evidence that the fellow was recruited and worked **full time** and exclusively on the action at the beneficiary's premises (or on secondment): this can include lab books, conference abstracts, library records, etc.
- Records and other supporting documentation on scientific and technical implementation of the action.
- **Timesheets are not an obligation for MSC Fellows** but can be used if in line with local practices.

Records must be kept for 5 years after payment of the balance (i.e. final payment)